Kindred Biosciences (KIN) Earning Somewhat Positive News Coverage, Report Finds
Headlines about Kindred Biosciences (NASDAQ:KIN) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kindred Biosciences earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.0011250670213 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have impacted Accern’s rankings:
- Edited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMT (finance.yahoo.com)
- Bank of New York Mellon : Buys Shares of 63,467 Kindred Biosciences, Inc (4-traders.com)
- Kindred Biosciences, Inc. (KIN) Issues Quarterly Earnings Results (americanbankingnews.com)
- Kindred Biosciences Announces Third Quarter 2017 Financial Results (bizjournals.com)
Shares of Kindred Biosciences (NASDAQ:KIN) traded down $0.10 during midday trading on Monday, hitting $7.15. The stock had a trading volume of 21,100 shares, compared to its average volume of 150,014. Kindred Biosciences has a one year low of $3.90 and a one year high of $9.65.
Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. analysts anticipate that Kindred Biosciences will post -1.18 EPS for the current year.
Separately, Zacks Investment Research lowered Kindred Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $9.19.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.